Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

NCT02273739 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Glioma
Angioimmunoblastic T-cell Lymphoma
Intrahepatic Cholangiocarcinoma
Chondrosarcoma

Interventions

DRUG: Enasidenib

Sponsor

Celgene

Collaborators

[object Object]